About: Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.76 (-1.74%)
EPRX NASDAQ Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc. Common Stock share price
EPRX price activity
Last Price
$6.760
Change (24hr)
-0.12 USD (1.74%)
Volume
659.52K
Volume (4w avg)
-
Open
$6.85
Day Range
$6.60 - $7.04
Previous Close
$6.88
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
EPRX price performance
Delayed
04 Nov, 9:00 pm GMT+0
EPRX details
EPRX Market Signals